In this study we show that FMD cycles alone delay melanoma but not lung cancer growth and show that FMD protects the heart from the adverse effects of immune therapy (anti-OX40/anti-PD-L1, anti-PD1/anti-CTLA4), by reducing autoimmune responses, lymphocyte infiltration and preventing inflammatory and oxidative damage in heart tissue in both the B16-F10 melanoma and LLC1 lung cancer models. This evidence concerns the gene CTLA4 and lung cancer.